Elevance Health stock has delivered a strong 36.9% return over the past year, and the current valuation checks now raise the question of whether that strength is still backed by a discount or already reflected in the price.

• Over the last 12 months, Elevance Health is up 36.9%, which puts recent buyers in a comfortable position and makes entry price more important for anyone considering the stock today.
• The company’s push to strengthen its connected cancer care model can support longer term cash flow expectations. The risk is that execution on these care programs and cost control may not fully support the current pricing implied by the market.
• On Simply Wall St’s broader checks, Elevance Health screens as attractively priced, with the stock looking undervalued in 5 of 6 valuation measures.

The issue now is whether Elevance Health’s recent share price gains still leave a genuine valuation cushion or mostly use it up.

Is Elevance Health Still Cheap on Earnings?

The P/E ratio suits Elevance Health because earnings are a core anchor for how investors assess large, established healthcare insurers. Elevance Health currently trades on a P/E of 17.2x, which is below the Healthcare industry average of 25.4x and also below the peer group average of 31.9x.

On Simply Wall St’s fair ratio framework, Elevance Health is estimated to have a P/E of around 34.1x based on its profile. That is roughly double the current multiple, which suggests the stock may appear undervalued on an earnings basis. Despite the recent focus on its connected cancer care model, which can influence sentiment and expectations, the market is still pricing Elevance Health at a notable discount to what this earnings-based model indicates.

On the P/E multiple, Elevance Health stock appears undervalued compared with both its fair ratio and typical healthcare peers.

The Elevance Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Elevance Health pick up where the P/E discussion leaves off and explain which combinations of future growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than its current price. Instead of providing a single output from a ratio or model, they outline the future conditions that underpin that figure so you can see how Elevance Health's actual progress compares with those expectations on the Community page.

The community sits on two very different scenarios for Elevance Health stock, with one side focused on margin recovery and the other on persistent pressure from government plans.

Bull case: 12% undervalued

"Strategic investments in digital consumer engagement and Carelon's diversified health services are accelerating revenue growth and providing higher-margin, recurring income streams..."

Bear case: 19% overvalued

"Elevated costs in government-backed plans and greater reliance on value-based care could compress margins despite operational improvements and diversification strategies..."

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

The Bottom Line

Elevance Health still screens as undervalued on market multiples, with the current P/E sitting well below both its tailored fair ratio and typical healthcare peers. That gap can be attractive if you think earnings quality and margins will hold up as the connected cancer care model and broader health services strategy develop. The main risk is that execution on these programs and cost control do not fully match what the current valuation implies. The crux for investors is whether the discount reflects genuine mispricing or fairly prices the uncertainty around future margins in government and value based plans.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.